AB0575 MESANGIAL C1Q DEPOSITION, BUT NOT C3 AND C1Q DEPOSITION IN OTHER RENAL COMPARTMENTS, IS A PREDICTOR OF RENAL OUTCOME IN LUPUS NEPHRITIS
نویسندگان
چکیده
Background Complement activation is an important pathophysiological process in the pathogenesis and development of systemic lupus erythematosus nephritis (LN). However, prognostic value complement factors deposition different kidney compartments has received little attention and, to best our knowledge, no study examined its association with renal outcomes LN. Objectives To evaluate significance C1q C3 tissue compartments. Methods We have conducted a retrospective cohort collected data on demographics, clinical laboratory parameters histopathology (light, immunofluorescent electron microsopy) at time biopsy after long-term follow-up. expression graded (mesangium, glomerular basement membrane (GBM), tubular (TBM) blood vessel wall) dichotomized into or low (grades 0 1) high 2 3). Remission (defined as complete partial remission) was defined per EULAR 2019 guidelines. Results A total 51 patients biopsy-proven LN were followed up for 4.5±2.9 years (80% women, mean age 38±14). 29 (71%) achieved remission. follows: mesangium (C1q 54%, 59%), GBM 34%, 41%), TBM 5%, 5%) wall 0%, 5%). Patients proliferative had more frequently (69% vs. 14%, p<0.001 72% 29%, p=0.005, respectively), while there differences between non-proliferative other (all p>0.05). Subjects who remission (64% 31%, p=0.045), but Interestingly, mesangial outcome significant even adjustment biopsy, gender type (proliferative non-proliferative) (OR 0.13 [0.02, 0.98], p=0.047). Conclusion might be factor aggressive treatment these may explain better patients. Disclosure Interests None declared
منابع مشابه
Decreased Circulating C3 Levels and Mesangial C3 Deposition Predict Renal Outcome in Patients with IgA Nephropathy
BACKGROUND AND AIMS Mesangial C3 deposition is frequently observed in patients with IgA nephropathy (IgAN). However, the role of complement in the pathogenesis or progression of IgAN is uncertain. In this observational cohort study, we aimed to identify the clinical implications of circulating C3 levels and mesangial C3 deposition and to investigate their utility as predictors of renal outcomes...
متن کاملSerum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis
BACKGROUND Lupus nephritis is considered to be a principal cause of morbidity and mortality in SLE. Few studies focus on the association between anti-C1q antibodies in circulation and renal C1q deposition in human lupus nephritis. In this study, we detected the serum levels of C1q, presence of anti-C1q antibodies in circulation, renal C1q deposition and further analyzed their associations with ...
متن کاملIncreased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?
OBJECTIVE Patients with systemic lupus erythematosus (SLE) have an increased risk of developing vascular diseases (VD) such as myocardial infarction, stroke and venous thrombosis, which can only partly be explained by traditional risk factors. The role of platelets in this process has not been extensively studied. Platelet activation supports complement binding to the platelet surface, and incr...
متن کاملCOMBINATION THERAPY WITH PULSE CYCLOPHOSPHAMIDE PLUS CORTICOSTEROIDS IMPROVES RENAL OUTCOME IN PATIENTS WITH LUPUS NEPHRITIS
ABSTRACT Background: The prognosis of SLE is int1uenced by the onset of glomerulonephtitis. Clinical ttials in lupus nephritis have demonstrated that cyclophosphamide therapy is the superior regimen in the management oflupus nephritis for preserving renal function. Objective: The purpose of this study is to define the outcome of renal function with bolus pu lses of cyclophosphamide and steroid...
متن کاملAnti-C1q antibodies in renal and non-renal SLE.
We read with interest the report of Marto et al on the occurrence of anti-C1q antibodies in systemic lupus erythematosus (SLE), particularly their finding of anti-C1q in 39.8% of patients with SLE without renal disease, 27.3% of whom went on to develop nephritis. We recently tested for anti-C1q antibodies using an enzyme linked immunosorbent assay (ELISA) kit (Buhlmann Laboratories, Basel) in t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the Rheumatic Diseases
سال: 2022
ISSN: ['1468-2060', '0003-4967']
DOI: https://doi.org/10.1136/annrheumdis-2022-eular.5363